Daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: final analysis of the phase 3 OCTANS Study
Annals of Hematology · 2024
DOI: 10.1007/s00277-024-05958-8 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Annals of Hematology, 2024. Verfasst von Weijun Fu und 17 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Changzheng Hospital, Shanghai, China. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Multiple Myeloma. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Janssen Research & Development, LLC.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Shanghai Changzheng Hospital, Shanghai, China.
- Seoul National University Bundang Hospital, Seongnam, South Korea.
- Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
- First Hospital of Jilin University, Changchun, China.
- Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
Förderung
- Janssen Research & Development, LLC
Zitieren
APA
Fu, W., Bang, S. M., Huang, H., Kim, K., Li, W., An, G., Lee, J. J., Cai, Z., Jin, J., Wang, Y., Chim, C. S., Carson, R., Liu, R., Zhao, M., Chen, X., Cui, C., Hou, J., & Wang, J. (2024). Daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: final analysis of the phase 3 OCTANS Study. Annals of Hematology. https://doi.org/10.1007/s00277-024-05958-8
Vancouver
Fu W, Bang SM, Huang H, Kim K, Li W, An G, et al. Daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: final analysis of the phase 3 OCTANS Study. Annals of Hematology. 2024. doi:10.1007/s00277-024-05958-8
BibTeX
@article{Fu2024,
author = {Fu, Weijun and Bang, Soo-Mee and Huang, Honghui and Kim, Kihyun and Li, Wei and An, Gang and Lee, Je-Jung and Cai, Zhen and Jin, Jie and Wang, Yafei and Chim, Chor Sang and Carson, Robin and Liu, Rui and Zhao, Man and Chen, Xi and Cui, Canchan and Hou, Jian and Wang, Jianxiang},
title = {Daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: final analysis of the phase 3 OCTANS Study},
journal = {Annals of Hematology},
year = {2024},
doi = {10.1007/s00277-024-05958-8}
}
EUVIMED